CLAIMS

1. A formulation comprising an anionic or polymeric surfactant, and a GLP-1-like peptide, provided that the surfactant is not sodium tauro-24,25-dihydrofusidate.

2. The formulation of **Claim 1** wherein the surfactant is selected from the group consisting of DSS (docusate sodium, CAS Registry Number [577-11-7]), docusate calcium [CAS number 128-49-4], docusate potassium [CAS number 7491-09-0], sodium dodecyl sulfate, sodium lauryl sulfate, sodium caprylate, sodium cholate, sodium deoxycholate, sodium taurocholate, and sodium glycocholate.

3. The formulation of **Claim 1**, wherein the surfactant is a polymeric (Tween®-40, Tween®-80, or Brij-35®) surfactant.

4. The formulation of **Claim 1**, wherein the GLP-1-like molecule has the amino acid sequence of SEQ ID NO:1; SEQ ID NO:4; or SEQ ID NO:5 or pharmaceutically acceptable salts thereof.

5. The formulation of **Claim 1**, wherein the GLP-1-like peptide is defined by the formula **R_1-SEQ ID NO:2-R_2**, or pharmaceutically acceptable salts thereof, wherein R_1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine, and R_2 is selected from the group consisting of Gly-OH or NH_2; or

the GLP-1-like peptide is defined by the formula R_1-SEQ ID NO:3-R_2 or pharmaceutically acceptable salts thereof,

wherein R_1 is selected from the group consisting of 4-imidazopropionyl, 4-imidazoacetyl, or 4-imidazo-α, α dimethyl-acetyl; and R_2 is selected from the group consisting of Gly-OH or NH_2.

6. The formulation of **Claim 1**, further comprising an isotonicity agent.

7. The formulation of **Claim 6**, wherein the isotonicity agent is glycerin.

8. The formulation of **Claim 6**, wherein the isotonicity agent is sodium chloride.

9. The formulation of **Claim 1**, further comprising a preservative.

10. The formulation of **Claim 9**, wherein the preservative is selected from the group consisting of m-cresol, phenol, methylparaben, and benzyl alcohol.

11. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 1** to the person.

12. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 2** to the person.

13. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 3** to the person.

14. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 4** to the person.

15. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 5** to the person.

16. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 6** to the person.

17. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 7** to the person.

18. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 8** to the person.

19. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 9** to the person.

20. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 10** to the person.

21. The method of **Claim 11**, wherein the condition is diabetes.

22. The method of **Claim 11**, wherein the condition is selected from the group consisting of obesity, myocardial infarction, catabolic states, and stroke.

23. The method of any one of **Claim 11** wherein the administration is oral.

Add A2